| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 71 | 1-year : | 82.93 |
| Resists | First : | 60.79 | Second : | 71 |
| Pivot price | 57.04  |
|||
| Supports | First : | 50.24 | Second : | 43.72 |
| MAs | MA(5) : | 56.35 |
MA(20) : | 56.04 |
| MA(100) : | 46.42 |
MA(250) : | 40.02 |
|
| MACD | MACD : | 2.2 |
Signal : | 2.7 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 44.8 |
| RSI | RSI(14): 61.7 |
|||
| 52-week | High : | 60.79 | Low : | 27.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ REX ] has closed above bottom band by 45.8%. Bollinger Bands are 36.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 57.84 - 58.06 | 58.06 - 58.28 |
| Low: | 55.4 - 55.66 | 55.66 - 55.93 |
| Close: | 56.38 - 56.79 | 56.79 - 57.19 |
Wed, 15 Feb 2017
The 10 Top Penny Stocks of 2017 - Money Morning
Fri, 18 Dec 2015
Why Martin Shkreli Was Arrested, the Definitive Explainer - Newsweek
Sun, 11 Oct 2015
Here's Why Orexigen Therapeutics' Stock Tanked in September - The Motley Fool
Mon, 17 Nov 2014
Janssen Is Working Its Way Toward Anti-Obesity - Seeking Alpha
Mon, 17 Nov 2014
2 Skyrocketing Biotech Stocks In A Stalling Market - Benzinga
Thu, 11 Sep 2014
Weight-Loss Drug from La Jolla Firm Gets FDA Approval - Times of San Diego
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 18 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 13.4 (%) |
| Held by Institutions | 82.7 (%) |
| Shares Short | 381 (K) |
| Shares Short P.Month | 299 (K) |
| EPS | 3.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 29.36 |
| Profit Margin | 7.3 % |
| Operating Margin | 12.2 % |
| Return on Assets (ttm) | 6.9 % |
| Return on Equity (ttm) | 13.8 % |
| Qtrly Rev. Growth | -6.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 47.62 |
| EBITDA (p.s.) | 4.95 |
| Qtrly Earnings Growth | 149.3 % |
| Operating Cash Flow | 128 (M) |
| Levered Free Cash Flow | 65 (M) |
| PE Ratio | 16.37 |
| PEG Ratio | 2.9 |
| Price to Book value | 1.93 |
| Price to Sales | 1.19 |
| Price to Cash Flow | 7.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|